Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the peripheral blood for collection by leukapheresis in patients undergoing peripheral blood progenitor cell collection and therapy.
Filgrastim was approved in the US in 1991 and there are biosimilars available with similar therapeutic indications. Tbo-filgrastim was approved by the FDA on August 29, 2012. Filgrastim-sndz was approved on March 6, 2015 and filgrastim-ayow was approved on March 2, 2022. A long-acting, pegylated G-CSF, pegfilgrastim, was made available to increase the duration of action of the drug.
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
Filgrastim is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia.
Filgrastim is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.
Filgrastim is indicated for the mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
Filgrastim is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia.
Filgrastim is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology, Muenster, Germany
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
University of Louisville, Louisville, Kentucky, United States
University of Nebraska, Omaha, Nebraska, United States
New York Medical College, Hawthorne, New York, United States
Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States
Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Hannover Medical School, Hannover, Germany
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.